News Channels

23 Jan 2023 REGENXBIO Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, is Active and Recruiting Patients
23 Jan 2023 TheracosBio Announces FDA Approval of Brenzavvy™ (bexagliflozin) for the Treatment of Adults with Type 2 Diabetes
23 Jan 2023 Neurogene Announces FDA Clearance of IND for NGN-401 Gene Therapy for Children with Rett Syndrome
23 Jan 2023 Disc Medicine Announces Exclusive Licensing Agreement with Mabwell Therapeutics for Novel Anti-TMPRSS6 Monoclonal Antibodies to Modulate Iron Homeostasis
23 Jan 2023 Priothera announces first patients enrolled in pivotal MO-TRANS global Phase 2b/3 study with mocravimod as an adjunctive and maintenance therapy for patients with Acute Myeloid Leukemia (AML) undergoing allogeneic Hematopoietic Cell Transplant (HCT)
23 Jan 2023 Ubiquigent collaborates with University of Glasgow on translational structural biology to accelerate drug discovery within the (de)ubiquitylation field
21 Jan 2023 Wugen Presents Data on WU-NK-101 in Combination with Cetuximab in Preclinical Models of Advanced Colorectal Cancer (CRC) at ASCO Gastrointestinal Cancers Symposium
21 Jan 2023 ADARx Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Clinical Study of ADX-324
21 Jan 2023 Ipsen presents Phase III NAPOLI 3 trial of Onivyde® regimen demonstrating positive survival results in previously untreated metastatic pancreatic ductal adenocarcinoma at ASCO GI
20 Jan 2023 Summit Therapeutics Closes Deal with Akeso Inc. to In-License Breakthrough Innovative Bispecific Antibody
20 Jan 2023 Dr. Reddy’s successfully completes full set of clinical studies of its rituximab biosimilar for filing in the U.S., Europe
20 Jan 2023 Sonnet BioTherapeutics Announces Pharmacokinetic and Pharmacodynamic Data in a Phase 1 Dose-Escalation Trial of SON-1010
20 Jan 2023 Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies
20 Jan 2023 Astellas Announces Hold Lifted by FDA on FORTIS Clinical Trial of AT845 Investigational Treatment for Adult Patients with Late-Onset Pompe Disease
20 Jan 2023 Hepagene Therapeutics Reports Positive Top-line Results for Phase 2a RISE Study of FXR Agonist HPG1860 in Patients with NASH
20 Jan 2023 Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma
20 Jan 2023 Mirati Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for First-in-Class Oral KRASG12D Selective Inhibitor, MRTX1133
20 Jan 2023 U.S. Food and Drug Administration Issues Complete Response Letter for Accelerated Approval of Donanemab
20 Jan 2023 Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata
20 Jan 2023 Stemedica Initiating Phase IIb/III Clinical Trial for Patients with Chronic Ischemic Stroke

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top